Biosign Update

Biosign Private Placement
As previously announced Biosign intends to complete a non-brokered
private placement of up to 5,000,000 units of Biosign ("Units") at
$0.10 per Unit for gross proceeds of up to $500,000 (the "Offering").
Each Unit will consist of one common share of Biosign and one-half of
one common share purchase warrant, with each full warrant (a "Warrant")
exercisable for one common share of Biosign at an exercise price of
$0.15 per share for a period of 12 months from closing. The Warrants
shall have an acceleration clause such that in the event that the
closing price of the Biosign common shares on the TSXV is in excess of
$0.20 for a period of five consecutive trading days, then Biosign will
have the right to accelerate the expiry date to 14 days following the
date of notice thereof given to the holders. Approval and price
protection for the private placement was received from the Toronto
Venture Exchange (TSX-V) on August 14th, 2012. The proceeds of the
private placement will be used for restructuring purposes and to
execute the new Company's business plan.

Shareholders of Biosign will be afforded the opportunity to participate
in the Offering on a pro rata basis, subject to compliance with applicable securities laws. Those
Biosign shareholders who desire to participate in the Offering are
encouraged to contact Biosign at the contact information below on or
before Friday September 7th, 2012. The Offering may be completed in one or more closings. The securities
issued in connection with the Offering are subject to a four-month hold
period under applicable securities laws.

Reduction in Payables
The Company has successfully restructured or has negotiated the
restructuring of a number of payments to creditors, subject to the
Offering being completed. The Company estimates that such
restructuring of payments to suppliers represents savings of
approximately $200,000.

Rebranding UFIT® ahead of US launch
The Company has renamed their "Automated Wrist Blood Pressure & Pulse
Rate Monitor with Computer Controls & Web Services" product. Previously
this system was known by its internal designation, "UFIT® TEN-10"
(which stands for "Uniform Fully Integrated Terminal Tensiometer-10").
As part of our new consumer-friendly commercialization strategy, this
product has been renamed the "Biosign Pulsewave™ Monitor". The
system's functions remain the same - an inflatable wrist cuff gathers a
pulse wave signal, the signal is transmitted to Biosign's servers for
analysis, and results are instantly transmitted back to the user, while
also being stored in the "Cloud" for remote retrieval & analysis.
Pulsewave™ is approved to deliver blood pressure, heart rate, pulse
variability and hemodynamic readings, while a Breathing Rate Average
(or BRA™) result is considered a "beta" release right now. As
previously announced on August 13th, 2012, an FDA premarket
notification 510(k) application has been filed for the Pulsewave™
system. Biosign will update its existing regulatory approvals from
Health Canada and CE Mark to reflect the new brand name.

Product Research & Validation Program
Under the new business plan, Biosign will pursue a focused research and
development agenda. Promoting and supporting our existing, approved and
market-ready products, including the Biosign Pulsewave™ Monitor and the
Healthanywhere™ suite of patient monitoring solutions will take
precedence. Management has re-prioritized the product pipeline. Going
forward the Company will concentrate on completing the development of
previously announced innovations that have the most potential to
generate immediate sales, including a screening tool for heart
arrhythmias (offering a new result called Total Anomaly Score or TAS™,
which indicates the potential degree of arrhythmia), as well as the
previously announced UFIT® TEN-20 blood glucose measurement function.

Business Development Activities
As part of an aggressive push to refocus efforts into sales & marketing,
the Management Team has engaged in productive discussions with a number
of key accounts. To date, a Letter of Intent has been signed to pursue
an exclusive marketing and distribution agreement with a US-based
provider of Health and Wellness solutions for large employers.
Negotiations have begun with a second counterparty to secure an
agreement to sell and support Biosign products to large hospital and
insurance clients in the United States and attention has been given to
refreshing, renegotiating and improving relationships with existing
Biosign distribution partners.

Biosign's CEO Mr. Robert Kaul stated: "In the past two weeks the team at
Biosign has made great strides in executing our ambitious plan to
restructure the Company. I'm thrilled to date with the response
received to our initiatives. We are looking forward to completing the
first phase of our plan by September 14th, 2012 when the Company anticipates closing the private placement.
Details of our new business plan and other pertinent information can be
found at www.biosign.com."

This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.